Search research articles
Contact Us
Filters
Showing results (201-210 of 282) with videos related to
Page
of 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
Plos One
|
May 29, 2019
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
Andrew J Armstrong, Santosh Gupta, Patrick Healy, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Targeted Oncology
|
October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Julie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2024
Reply to J.A. Garcia et al
Susan Halabi, Siyuan Guo, Akash Roy, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 282) with videos related to
Sort By:
Page
of 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2024
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
Susan Halabi, Akash Roy, Larysa Rydzewska, et al.
JCO Precision Oncology
|
June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With <i>ERBB2</i> Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Apar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology
|
April 7, 2023
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study
Eugene R Ahn, Michael Rothe, Pam K Mangat, et al.
Plos One
|
May 29, 2019
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
Andrew J Armstrong, Santosh Gupta, Patrick Healy, et al.
Cancer Medicine
|
December 26, 2025
Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS
Matthias Saar, Karim Fizazi, Neal D Shore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
Howard I Scher, Susan Halabi, Ian Tannock, et al.
JCO Precision Oncology
|
November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology
|
April 11, 2024
Regorafenib in Patients With Solid Tumors With <i>BRAF</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Vaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Targeted Oncology
|
October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Julie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2024
Reply to J.A. Garcia et al
Susan Halabi, Siyuan Guo, Akash Roy, et al.
Page
of 29